Compare SGP & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGP | FLGT |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 932.9M | 867.4M |
| IPO Year | N/A | 2016 |
| Metric | SGP | FLGT |
|---|---|---|
| Price | $26.68 | $14.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $47.00 | $28.33 |
| AVG Volume (30 Days) | 82.4K | ★ 486.9K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | N/A | $10.66 |
| Revenue Next Year | N/A | $12.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.71 | $13.46 |
| 52 Week High | $30.56 | $31.04 |
| Indicator | SGP | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 20.89 |
| Support Level | $25.50 | N/A |
| Resistance Level | $30.02 | $19.96 |
| Average True Range (ATR) | 1.60 | 0.99 |
| MACD | -0.30 | -0.83 |
| Stochastic Oscillator | 29.00 | 9.87 |
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.